Zika Viral Vector Assembly for Blood-Brain Barrier Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy systems lack efficient, specific, and safe methods for delivering therapeutic transgenes, particularly for brain diseases and neurological syndromes, due to inadequate DNA delivery systems that fail to cross the blood-brain barrier and persist in the CNS.
Innovation Solution
Development of recombinantly modified Zika virus (ZIKV) particles as a gene delivery system, assembled in vitro using a trans-complementation method, which includes a 5' UTR, heterologous genes, and a 3' UTR, capable of crossing the blood-brain barrier and persisting in the CNS, and can be manipulated to express therapeutic genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing viral vectors (Lentiviral, AAV) are used for gene delivery, then gene delivery capability is achieved, but ability to cross blood-brain barrier and persist in CNS is insufficient
Solution Approach 1:
The patent uses Zika virus particles as an intermediary delivery vehicle that naturally possesses the ability to cross the blood-brain barrier. The ZIKV particle serves as a mediator between the therapeutic transgene and target cells in the CNS, leveraging the virus's natural tropism for neural tissue to achieve delivery where conventional vectors fail.
Solution Approach 2:
The invention modifies the Zika virus genome by inserting heterologous genes (therapeutic transgenes) into specific locations within the viral genome structure. This genetic parameter change allows the virus to maintain its natural ability to cross the blood-brain barrier while simultaneously providing gene delivery capability that conventional vectors lack.
2Ease of operation
If recombinantly modified ZIKV particles are assembled in vitro using trans-complementation method, then ease of manipulation and safety are improved, but manufacturing complexity increases
Solution Approach 1:
The manufacturing process is divided into separate functional components: the ZIKV particle assembly is performed in vitro using a trans-complementation method where different viral proteins are expressed separately and then assembled. This segmentation allows for controlled production and easier manipulation of each component before final assembly, improving safety and ease of operation despite increased procedural steps.
Solution Approach 2:
The patent performs preliminary assembly and characterization of ZIKV particles in vitro before in vivo application. The trans-complementation method allows researchers to pre-assemble particles with desired genetic modifications and verify their properties before administering to subjects, thereby improving ease of manipulation and reducing risks.
3Adaptability or versatility
If heterologous genes are inserted into ZIKV genome, then therapeutic gene expression capability is improved, but viral genome stability may be affected
Solution Approach 1:
The patent inserts heterologous genes into specific, predetermined locations within the ZIKV genome rather than random insertion. By selecting specific genomic regions for transgene integration, the invention maintains local genome stability while providing the desired therapeutic gene expression capability. The heterologous genes are placed in locations that minimize disruption to essential viral functions.
Data Source
AI summary
The disclosure provides for recombinantly modified Zika-based vectors that can be used in gene therapy applications.